Eli Lilly presented Phase 2b results at the 62nd annual meeting of the European Association for the Study of Diabetes (EASD) in Milan on 30 September 2026 for eloraTZP, a fixed combination of the amylin-receptor agonist eloralintide with the dual GIP/GLP-1 agonist tirzepatide. Neither eloralintide nor the combination holds a marketing authorisation in the UK, and no submission has been made to the MHRA. The data describe a research finding in a trial population; they are not a licensed treatment and should be read in that context.
What the trial reported
The Phase 2b study (NCT06603571) enrolled 367 adults with obesity or overweight and type 2 diabetes and ran for 48 weeks. On the efficacy estimand — which ignores discontinuations and other deviations from the assigned regimen — the highest-dose combination produced a mean weight reduction of 23.3% from baseline, against 14.8% for tirzepatide 15 mg alone, 12.3% for eloralintide alone and about 3% for placebo. Mean HbA1c fell by 2.9 percentage points on the highest-dose combination, against 2.4 points for tirzepatide alone and 0.3 points for placebo. Lilly reported that all dose combinations met the primary and secondary endpoints.
The tolerability caveat
The discontinuation picture was less clean. Across the combination's dose range, between 10.8% and 27% of participants stopped treatment because of an adverse event, against 0% to 10.8% for eloralintide alone, 2.9% for tirzepatide alone and 16.7% for placebo. Lilly's Ken Custer told a press conference that a 48-week study escalating two drugs at once makes final tolerability hard to profile, and said the Phase 3 programme would run longer with an optimised escalation schedule. That is a statement of intent, not evidence: the tolerability question stays open until the Phase 3 data exist.
Why the amylin mechanism attracts attention
Eloralintide is an amylin-receptor agonist. Lilly's Dan Skovronsky described it as an attempt to be preferential for amylin rather than calcitonin — a selectivity problem, because amylin-receptor agonists can also engage the calcitonin system in the thyroid, which bears on calcium handling. Lilly plans to start Phase 3 of the combination in the fourth quarter of 2026; eloralintide is also being studied as monotherapy in the Phase 3 ENLIGHTEN-1 trial, with primary completion set for March 2028. Any benefit suggested by a 48-week Phase 2b study is provisional until those larger trials report.
The UK position
There is no MHRA marketing authorisation for eloralintide or for the eloraTZP combination. None of the amylin-receptor agonists discussed here is currently licensed in the UK, and none is available on the NHS or by private prescription. Under the Medicines Act 1968 and the Human Medicines Regulations 2012, unlicensed peptides sold for research remain research-use-only materials; they are not medicines, and this article describes trial results rather than any product available to buy.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.